187 |
S3 in Transforming Patient Treatment Practice (Patient Selection, Length of Stay, etc.) |
Raj Makkar |
Apr. 21. 16 |
186 |
Sapien 3 Clinical Update |
Martin Bert Leon |
Apr. 21. 16 |
185 |
Sapien 3 Technology Overview |
Alain G. Cribier |
Apr. 21. 16 |
184 |
Extremely High Risk for TAVR - Insights from QOL and Cost-Effectiveness Studies |
David Joel Cohen |
Apr. 21. 16 |
183 |
TAVR for Bicuspid AS |
Sung Han Yoon |
Apr. 21. 16 |
182 |
Valve Thrombosis/Leaflet Thickening: To Treat or Not to Treat |
Raj Makkar |
Apr. 21. 16 |
181 |
Paravalvular Regurgitation After TAVR: Insights from PARTNER II S3HR and S3i |
Susheel Kodali |
Apr. 21. 16 |
180 |
TAVR - Year in Review |
Raj Makkar |
Apr. 21. 16 |
179 |
PARTNER 2A - TAVR in Intermediate Risk Patients |
Martin Bert Leon |
Apr. 21. 16 |
178 |
Top 10 Lessons for Complication-Free TAVR |
Susheel Kodali |
Apr. 21. 16 |